Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia
Sponsor: Nantes University Hospital
Summary
This is a phase 1, open label, interventional, single center, in patients with Acute Myeloid Leukemia (AML). This study will investigate dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy. The patient population will consist of adults men and women at least 18 years, who meet eligibility criteria. In this study propose combining tocilizumab with the standard treatment of azacitidine and venetoclax for patients with AML who are not eligible for intensive treatment.
Official title: Single-Center Phase 1 Study With Escalating Doses of Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia (AML). TOCIVENA
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-03-10
Completion Date
2030-07-10
Last Updated
2026-02-17
Healthy Volunteers
No
Conditions
Interventions
increase dose of tocilizumab
Combining tocilizumab with the standard treatment of azacitidine and venetoclax
Locations (1)
CHU of Nantes
Nantes, France